Becton Dickinson/Clontech Laboratories
This article was originally published in The Gray Sheet
Executive Summary
BD expects to complete its acquisition of molecular biology research products maker Clontech by Aug. 31. Under a revision of their April 28 merger agreement (1"The Gray Sheet" May 3, p. 13), the deal will now be for $200 mil. in cash instead of stock
You may also be interested in...
Becton's $200 Mil. Clontech Buy Broadens Life Science Research Offerings
Becton Dickinson's $200 mil. acquisition of molecular biology research products maker Clontech Labs will significantly broaden the BD Biosciences life science research product line, according to the company.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.